SG10201912703PA - Targeted expression of chloride channels and methods of use thereof - Google Patents

Targeted expression of chloride channels and methods of use thereof

Info

Publication number
SG10201912703PA
SG10201912703PA SG10201912703PA SG10201912703PA SG10201912703PA SG 10201912703P A SG10201912703P A SG 10201912703PA SG 10201912703P A SG10201912703P A SG 10201912703PA SG 10201912703P A SG10201912703P A SG 10201912703PA SG 10201912703P A SG10201912703P A SG 10201912703PA
Authority
SG
Singapore
Prior art keywords
methods
chloride channels
targeted expression
targeted
expression
Prior art date
Application number
SG10201912703PA
Other languages
English (en)
Inventor
Griffith Roger Thomas
Shawnalea Jimee Frazier
Original Assignee
Goleini Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goleini Inc filed Critical Goleini Inc
Publication of SG10201912703PA publication Critical patent/SG10201912703PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201912703PA 2015-10-01 2016-09-28 Targeted expression of chloride channels and methods of use thereof SG10201912703PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235920P 2015-10-01 2015-10-01
US201562235914P 2015-10-01 2015-10-01
US201662303907P 2016-03-04 2016-03-04
US201662378509P 2016-08-23 2016-08-23

Publications (1)

Publication Number Publication Date
SG10201912703PA true SG10201912703PA (en) 2020-02-27

Family

ID=58427328

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912703PA SG10201912703PA (en) 2015-10-01 2016-09-28 Targeted expression of chloride channels and methods of use thereof

Country Status (11)

Country Link
US (1) US11407812B2 (de)
EP (1) EP3355938B1 (de)
JP (1) JP7097070B2 (de)
KR (1) KR20180072713A (de)
CN (1) CN108289965A (de)
AU (1) AU2016332847B2 (de)
BR (1) BR112018006480A2 (de)
CA (1) CA2999279A1 (de)
HK (1) HK1252915A1 (de)
SG (1) SG10201912703PA (de)
WO (1) WO2017058926A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110679548B (zh) * 2019-10-24 2021-11-30 南方医科大学南方医院 一种自闭症小鼠模型的构建方法
CN111759857A (zh) * 2020-06-30 2020-10-13 宁波市微循环与莨菪类药研究所 Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用
CN115480485B (zh) * 2022-09-14 2024-09-10 南开大学 一种基于数据驱动模型的软镜扭转运动安全控制方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644643A (en) * 1969-10-13 1972-02-22 Unimed Inc Method of reducing intraocular pressure using glycine
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5527703A (en) 1994-05-25 1996-06-18 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
EP1767637A1 (de) 2000-06-20 2007-03-28 Bionomics Limited Mutation, welche mit Epilepsie assoziiert ist
EP1430121A4 (de) * 2001-02-16 2004-09-22 Bristol Myers Squibb Co Eine neue, im magen-darm-trakt exprimierte glycinrezeptor-alpha-untereinheit, hgra4, codierende polynukleotide und spleissvariante davon
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2007127428A2 (en) * 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
WO2008024998A2 (en) 2006-08-24 2008-02-28 Virovek, Inc. Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
EP2058401A1 (de) * 2007-10-05 2009-05-13 Genethon Weitverbreitete Genverabreichung an Motorneuronen unter Verwendung einer peripheren Injektion von AAV-Vektoren
EP2283038A1 (de) * 2008-04-30 2011-02-16 Dublin City University Zusammensetzungen und verfahren zur in-frame-expression multimerer proteine
EP2344636B1 (de) 2008-10-09 2017-12-06 Howard Hughes Medical Institute Neue chimäre ligandgesteuerte ionenkanäle und anwendungsverfahren dafür
US20130184318A1 (en) 2010-04-30 2013-07-18 The Regents Of The University Of California Modulating compliance of trabecular meshwork
WO2012155091A1 (en) 2011-05-11 2012-11-15 Kirax Corporation Package for improved treatment of conditions
AU2013293270B2 (en) * 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
WO2014093251A1 (en) * 2012-12-10 2014-06-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Engineered receptors and their use
CN106102833A (zh) 2014-01-08 2016-11-09 电路治疗公司 用于治疗性管理高眼压的方法
EP3122424A4 (de) 2014-03-27 2017-12-06 Circuit Therapeutics, Inc. System und verfahren für das therapeutische management von husten
CA2963168A1 (en) 2014-10-06 2016-04-14 Arthrogen B.V. Aav-based gene therapy
CN108348528A (zh) 2015-09-17 2018-07-31 科达生物治疗公司 治疗神经障碍的组合物和方法
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
IL261665B2 (en) 2016-04-21 2023-11-01 Virovek Inc AVV production in insect cells, methods and preparations thereof

Also Published As

Publication number Publication date
CN108289965A (zh) 2018-07-17
BR112018006480A2 (pt) 2018-10-09
JP7097070B2 (ja) 2022-07-07
EP3355938A4 (de) 2019-03-06
WO2017058926A1 (en) 2017-04-06
AU2016332847A2 (en) 2023-08-03
US11407812B2 (en) 2022-08-09
CA2999279A1 (en) 2017-04-06
JP2018533976A (ja) 2018-11-22
US20190010210A1 (en) 2019-01-10
KR20180072713A (ko) 2018-06-29
EP3355938A1 (de) 2018-08-08
EP3355938B1 (de) 2024-02-07
AU2016332847B2 (en) 2023-08-10
HK1252915A1 (zh) 2019-06-06
AU2016332847A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
HUS2400028I1 (hu) PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
HK1252827A1 (zh) 結合lag-3的分子和其使用方法
IL250415B (en) Antibodies against pd-l and methods of using them
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
PT3548033T (pt) Compostos e respectivos métodos de utilização
IL282482A (en) Variants of protoxin-II and methods of use
IL265359A (en) Modified Oligonucleotides and Methods of Use
IL282508A (en) Variants of protoxin-II and methods of use
IL249894A0 (en) Targeted medical nanoparticles and methods for their preparation and use
IL254783A0 (en) Combinations for deworming methods for using them
HK1252915A1 (zh) 氯離子通道的靶向表達及其使用方法
HK1258056A1 (zh) 治療性化合物和其使用方法
GB201501469D0 (en) Garment and method of use thereof
GB201416797D0 (en) Contianer and method of use thereof